Literature DB >> 31498183

Does the Artery-first Approach Improve the Rate of R0 Resection in Pancreatoduodenectomy?: A Multicenter, Randomized, Controlled Trial.

Luis Sabater1, Esteban Cugat2, Alejandro Serrablo3, Gonzalo Suarez-Artacho4, Luis Diez-Valladares5, Julio Santoyo-Santoyo6, Elena Martín-Pérez7, Fabio Ausania8, Santiago Lopez-Ben9, Jose Maria Jover-Navalon10, Marina Garcés-Albir1, Maria Isabel Garcia-Domingo2, Mario Serradilla3, Elia Pérez-Aguirre5, Belinda Sánchez-Pérez6, Marcello Di Martino7, Paula Senra-Del-Rio8, Laia Falgueras-Verdaguer9, Alberto Carabias10, Mari Carmen Gómez-Mateo11, Antonio Ferrandez12, Dimitri Dorcaratto1, Elena Muñoz-Forner1, Constantino Fondevila13, Javier Padillo4.   

Abstract

OBJECTIVE: To compare the rates of R0 resection in pancreatoduodenectomy (PD) for pancreatic and periampullary malignant tumors by means of standard (ST-PD) versus artery-first approach (AFA-PD).
BACKGROUND: Standardized histological examination of PD specimens has shown that most pancreatic resections thought to be R0 resections are R1. "Artery-first approach" is a surgical technique characterized by meticulous dissection of arterial planes and clearing of retropancreatic tissue in an attempt to achieve a higher rate of R0. To date, studies comparing AFA-PD versus ST-PD are retrospective cohort or case-control studies.
METHODS: A multicenter, randomized, controlled trial was conducted in 10 University Hospitals (NCT02803814, ClinicalTrials.gov). Eligible patients were those who presented with pancreatic head adenocarcinoma and periampullary tumors (ampulloma, distal cholangiocarcinoma, duodenal adenocarcinoma). Assignment to each group (ST-PD or AFA-PD) was randomized by blocks and stratified by centers. The primary end-point was the rate of tumor-free resection margins (R0); secondary end-points were postoperative complications and mortality.
RESULTS: One hundred seventy-nine patients were assessed for eligibility and 176 randomized. After exclusions, the final analysis included 75 ST-PD and 78 AFA-PD. R0 resection rates were 77.3% (95% CI: 68.4-87.4) with ST-PD and 67.9% (95% CI: 58.3-79.1) with AFA-PD, P=0.194. There were no significant differences in postoperative complication rates, overall 73.3% versus 67.9%, and perioperative mortality 4% versus 6.4%.
CONCLUSIONS: Despite theoretical oncological advantages associated with AFA-PD and evidence coming from low-level studies, this multicenter, randomized, controlled trial has found no difference neither in R0 resection rates nor in postoperative complications in patients undergoing ST-PD versus AFA-PD for pancreatic head adenocarcinoma and other periampullary tumors.

Entities:  

Mesh:

Year:  2019        PMID: 31498183     DOI: 10.1097/SLA.0000000000003535

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  9 in total

1.  Robotic Artery-First Approach During Pancreatoduodenectomy.

Authors:  Marcel Autran Machado; Bruno V Mattos; Murillo Macedo Lobo Filho; Fabio Ferrari Makdissi
Journal:  Ann Surg Oncol       Date:  2021-03-06       Impact factor: 5.344

2.  Comparison of perioperative outcomes in pancreatic head cancer patients following either a laparoscopic or open pancreaticoduodenectomy with a superior mesenteric artery first approach.

Authors:  Min Young Park; Woohyung Lee; Jaewoo Kwon; Ki Byung Song; Dae Wook Hwang; Jae Hoon Lee; Song Cheol Kim
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2021-08-31

3.  Prognostic factors for long-term survival after pancreaticoduodenectomy for periampullary adenocarcinoma. A retrospective cohort study.

Authors:  Hazem Zakaria; Ahmed N Sallam; Islam I Ayoub; Emad H Gad; Mohammad Taha; Michael R Roshdy; Dina Sweed; Nahla K Gaballa; Taha Yassein
Journal:  Ann Med Surg (Lond)       Date:  2020-08-11

Review 4.  What do surgeons need to know about the mesopancreas.

Authors:  Eduardo de Souza M Fernandes; Oliver Strobel; Camila Girão; Jose Maria A Moraes-Junior; Orlando Jorge M Torres
Journal:  Langenbecks Arch Surg       Date:  2021-06-12       Impact factor: 3.445

5.  Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre.

Authors:  Susana Roselló; Claudio Pizzo; Luis Sabater; Andrés Cervantes; Marisol Huerta; Elena Muñoz; Roberto Aliaga; Almudena Vera; Clara Alfaro-Cervelló; Esther Jordá; Marina Garcés-Albir; Desamparados Roda; Dimitri Dorcaratto; Noelia Tarazona; Sergio Torondel; Jorge Guijarro; Vicente Sánchiz; Valentina Gambardella; Tania Fleitas-Kanonnikoff; Paloma Lluch; Isabel Pascual; Antonio Ferrández
Journal:  ESMO Open       Date:  2020-11

6.  Development and Validation of a Nomogram to Predict Survival in Pancreatic Head Ductal Adenocarcinoma After Pancreaticoduodenectomy.

Authors:  Feng Peng; Tingting Qin; Min Wang; Hebin Wang; Chao Dang; Chien-Hui Wu; Yu-Wen Tien; Renyi Qin
Journal:  Front Oncol       Date:  2021-09-29       Impact factor: 6.244

7.  Korean Surgical Practice Guideline for Pancreatic Cancer 2022: A summary of evidence-based surgical approaches

Authors:  Seung Eun Lee; Sung-Sik Han; Chang Moo Kang; Wooil Kwon; Kwang Yeol Paik; Ki Byung Song; Jae Do Yang; Jun Chul Chung; Chi-Young Jeong; Sun-Whe Kim
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2022-02-28

Review 8.  State-of-the-art surgery for pancreatic cancer.

Authors:  Anna Nießen; Thilo Hackert
Journal:  Langenbecks Arch Surg       Date:  2021-11-09       Impact factor: 2.895

9.  Circulating Tumor Cells Enumeration from the Portal Vein for Risk Stratification in Early Pancreatic Cancer Patients.

Authors:  Javier Padillo-Ruiz; Gonzalo Suarez; Sheila Pereira; Francisco José Calero-Castro; Jose Tinoco; Luis Marin; Carmen Bernal; Carmen Cepeda-Franco; Jose Maria Alamo; Francisco Almoguera; Hada C Macher; Paula Villanueva; Francisco José García-Fernandez; Inmaculada Gallego; Manuel Romero; Miguel Angel Gomez-Bravo; Valeria Denninghoff; María José Serrano
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.